murabutide and Tuberculosis

murabutide has been researched along with Tuberculosis* in 1 studies

Other Studies

1 other study(ies) available for murabutide and Tuberculosis

Article	Year
Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection. Human vaccines & immunotherapeutics, 2017, 12-02, Volume: 13, Issue:12 Tuberculosis (TB) remains a main public health concern and 10.4 million new cases occurred in 2015 around the world. BCG is the only approved vaccine against TB, but has variable efficacy and new vaccines are needed. We developed two new mTB vaccine candidates based on the recombinant fusion proteins, rCMX and rECMX formulated with Advax4, a new combination adjuvant combining delta inulin, CpG oligonucleotide and murabutide. BALB/c mice were immunized three times intramuscularly with these vaccine formulations. Injection of Advax4 alone increased the percentage of lymphatic endothelial cells and activated macrophages (F480/CD11b Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Load; Female; Humans; Immunoglobulin G; Inulin; Lung; Lymph Nodes; Mice, Inbred BALB C; Mycobacterium tuberculosis; Oligodeoxyribonucleotides; Recombinant Fusion Proteins; Th1 Cells; Treatment Outcome; Tuberculosis; Tuberculosis Vaccines; Vaccines, Synthetic	2017

Article

Year

Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.

Human vaccines & immunotherapeutics, 2017, 12-02, Volume: 13, Issue:12

Tuberculosis (TB) remains a main public health concern and 10.4 million new cases occurred in 2015 around the world. BCG is the only approved vaccine against TB, but has variable efficacy and new vaccines are needed. We developed two new mTB vaccine candidates based on the recombinant fusion proteins, rCMX and rECMX formulated with Advax4, a new combination adjuvant combining delta inulin, CpG oligonucleotide and murabutide. BALB/c mice were immunized three times intramuscularly with these vaccine formulations. Injection of Advax4 alone increased the percentage of lymphatic endothelial cells and activated macrophages (F480/CD11b

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Load; Female; Humans; Immunoglobulin G; Inulin; Lung; Lymph Nodes; Mice, Inbred BALB C; Mycobacterium tuberculosis; Oligodeoxyribonucleotides; Recombinant Fusion Proteins; Th1 Cells; Treatment Outcome; Tuberculosis; Tuberculosis Vaccines; Vaccines, Synthetic

2017